CRO Execution for Adaptive Oncology Trial Designs

Adaptive trial designs — those that incorporate pre-specified modifications based on interim data — have become increasingly common in oncology development. They offer efficiency advantages in early-phase programs and can support faster dose selection, population enrichment, or go/no-go decisions without requiring a full new study.

The operational demands of an adaptive design are substantially higher than a conventional fixed design. Sitero is experienced in executing adaptive oncology trials, where the ability to respond to interim findings without disrupting ongoing operations is critical.

What Makes Adaptive Trials Operationally Demanding

In a conventional trial, the protocol is fixed and operations follow a predictable path. In an adaptive trial, interim analyses may trigger changes to the randomization scheme, cohort composition, dosing arms, or eligibility criteria. These changes need to be executed cleanly, documented properly, and communicated to sites without compromising blinding or introducing operational inconsistency.

This requires tight alignment between the clinical operations team, the RTSM/IRT system, the data management team, and the DSMB or independent data monitoring committee. A disconnect at any point can compromise the integrity of the adaptation.

RTSM as the Operational Backbone

In adaptive oncology trials, the RTSM system is not just a randomization tool — it is the mechanism through which protocol adaptations are executed in real time. When cohort assignments change based on interim data, the RTSM must be updated accurately and quickly, with full audit trail documentation. Sitero’s integrated RTSM supports adaptive schemes including dose escalation, cohort expansion, and arm dropping.

Data Readiness for Interim Analysis

Interim analyses are only as good as the data that feeds them. Sitero’s data management and biometrics teams work to defined data cleaning timelines that ensure the interim dataset is analysis-ready when the DSMB or sponsor needs it. A 60% decrease in data management closeout timelines across our oncology programs reflects the discipline built into our data operations — discipline that matters even more at interim than at final closeout.

Operational Continuity During Adaptations

Sites need to continue enrolling and treating patients while adaptations are being assessed and implemented. Sitero’s clinical operations team manages site communication, updated protocol training, and operational continuity during adaptation periods to minimize disruption and maintain enrollment momentum.